Evidence map›Paper›PMID 39843940›Full record

Trial reportNature medicine2025

First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.

Lin Shen, Yanqiao Zhang, Ziyu Li, Xiaotian Zhang, Xiangyu Gao, Bo Liu, Yusheng Wang, Yi Ba, Ning Li, Ruixing Zhang and 80 more

Erratum issuedAbstract readRandomized Controlled TrialClinical Trial, Phase IIIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 79 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

90 authors.

Lin Shen *State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing, China.ORCID http://orcid.org/0000-0003-1134-2922
Yanqiao Zhang *Harbin Medical University Cancer Hospital, Harbin, China.
Ziyu Li *Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing, China.ORCID http://orcid.org/0000-0001-5580-4979
Xiaotian Zhang *State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing, China.
Xiangyu Gao *State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing, China.ORCID http://orcid.org/0000-0002-1697-1157
Bo LiuDepartment of Gastroenterology, Shandong Cancer Hospital, Jinan, China.
Yusheng WangShanxi Provincial Cancer Hospital, Taiyuan, China.
Yi BaTianjin Medical University Cancer Institute & Hospital, Tianjin, China.
Ning LiHenan Cancer Hospital, Zhengzhou, China.
Ruixing ZhangThe Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Jingdong ZhangLiaoning Cancer Hospital & Institute, Shenyang, China.
Ye ChenThe First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
Jian ChenYantai Yuhuangding Hospital, Yantai, China.
Mingzhu HuangFudan University Shanghai Cancer Center, Shanghai, China.
Yang FuThe First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Mulin LiuThe First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
Zheng LiuHandan Central Hospital, Handan, China.
Jun ZhaoChangzhi People's Hospital, Changzhi, China.
Wei LiThe First Bethune Hospital of Jilin University, Changchun, China.
Jia WeiNanjing Drum Tower Hospital, Nanjing, China.ORCID http://orcid.org/0000-0003-3024-8878
Changzheng LiDepartment of Gastroenterology, Shandong Cancer Hospital, Jinan, China.
Nong XuThe First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zengqing GuoFujian Cancer Hospital, Fuzhou, China.
Bangwei CaoBeijing Friendship Hospital, Capital Medical University, Beijing, China.
Lian LiuQilu Hospital of Shandong University, Jinan, China.
Peng NieGansu Wuwei Tumour Hospital, Wuwei, China.
Lixin WanNanyang Central Hospital, Nanyang, China.
Lili ShengThe First Affiliated Hospital of Wannan Medical College, Wuhu, China.
Zhenyang LiuHunan Cancer Hospital, Changsha, China.
Yifu HeAnhui Provincial Cancer Hospital, Hefei, China.
Kangsheng GuThe First Affiliated Hospital of Anhui Medical University, Hefei, China.
Guowu WuMeizhou People's Hospital, Meizhou, China.
Weibo WangShandong Provincial Hospital, Jinan, China.
Futong ZhangShijiazhuang People's Hospital, Shijiazhuang, China.
Wensheng QiuThe Affiliated Hospital of Qingdao University, Qingdao, China.
Jun GuoXingtai People's Hospital, Xingtai, China.
Jieer YingZhejiang Cancer Hospital, Hangzhou, China.
Hongming PanSir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Huiting XuHubei Cancer Hospital, Wuhan, China.
Yuan YuanXuzhou Central Hospital, Xuzhou, China.
Yuansong BaiThe Third Bethune Hospital of Jilin University, Changchun, China.
Zhenghua WangThe First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
Jiye XuZhoukou Central Hospital, Zhoukou, China.
Xuehong ZhaoLinfen Central Hospital, Linfen, China.
Hao LiuSichuan Provincial People's Hospital, Chengdu, China.
Xizhi ZhangNorthern Jiangsu People's Hospital, Yangzhou, China.
Wenxiang DaiThe First Affiliated Hospital of The University of South China, Hengyang, China.
Hongyan XuWeihai Municipal Hospital, Weihai, China.
Ming LiuWest China Hospital of Sichuan University, Chengdu, China.
Lin XieYunnan Cancer Hospital, Kunming, China.
Yong TangAffiliated Cancer Hospital of Xinjiang Medical University, Urumqi, China.
Jianying JinTaizhou Hospital of Zhejiang Province, Linhai, China.
Xiujuan QuThe First Hospital of China Medical University, Shenyang, China.
Xuefeng FangThe Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Mingwei HuangGuangxi Medical University Cancer Hospital, Nanning, China.
Hao ChenThe Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Zhendong ZhengGeneral Hospital of Northern Theater Command, Shenyang, China.
Ying WangShengjing Hospital of China Medical University, Shenyang, China.
Daqing WangHengshui People's Hospital (Harrison International Peace Hospital), Hengshui, China.
Xiaoqin LiAffiliated Hospital of Jiangsu University, Zhenjiang, China.
Guohua YuWeifang People's Hospital, Weifang, China.
Haiyan LiuThe Second Affiliated Hospital of Shandong First Medical University, Tai'an, China.
Yongjian ZhouFujian Medical University Union Hospital, Fuzhou, China.
Diansheng ZhongTianjin Medical University General Hospital, Tianjin, China.
Shan ZengXiangya Hospital Central South University, Changsha, China.
Mafei KangAffiliated Hospital of Guilin Medical University, Guilin, China.
Meiqing WangHainan Cancer Hospital, Haikou, China.
Yong GaoHuai'an First People's Hospital, Huai'an, China.
Wenxin LiInner Mongolia Autonomous Region People's Hospital, Hohhot, China.
Zejun WangThe Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China.
Minghui ZhangChifeng Municipal Hospital, Chifeng, China.
Jinghua ZhangCangzhou Central Hospital, Cangzhou, China.
Qingshan LiAffiliated Hospital of Chengde Medical University, Chengde, China.
Shujuan SunDaqing People's Hospital, Daqing, China.
Aimin ZangAffiliated Hospital of Hebei University, Baoding, China.
Lizhu LinThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Ming XieAffiliated Hospital of Zunyi Medical University, Zunyi, China.
Zhixiang ZhuangThe Second Affiliated Hospital of Soochow University, Suzhou, China.
Tao ZhangYuebei People's Hospital, Shaoguan, China.
Zhifang YaoAkeso Biopharma Inc., Zhongshan, China.
Dongmei LuAkeso Biopharma Inc., Zhongshan, China.
Wei LiuAkeso Biopharma Inc., Zhongshan, China.
Mingxiu HuAkeso Biopharma Inc., Zhongshan, China.
Zhongmin Maxwell WangAkeso Biopharma Inc., Zhongshan, China.ORCID http://orcid.org/0000-0002-1683-5147
Baiyong LiAkeso Biopharma Inc., Zhongshan, China.
Michelle XiaAkeso Biopharma Inc., Zhongshan, China.
Jiajia ZhangUniversity of California Los Angeles Health, Los Angeles, CA, USA.
Xiangji YingDepartment of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA.
Drew M PardollThe Bloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-6215-1013
Jiafu JiState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing, China. jijiafu@hsc.pku.edu.cn.ORCID http://orcid.org/0000-0001-6878-5543

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82272655National Natural Science Foundation of China (National Science Foundation of China) 82373438National Natural Science Foundation of China (National Science Foundation of China) 92259302
6 · The paper itself

Abstract

Programmed cell death protein-1 (PD-1) inhibitors plus chemotherapy have been the standard of care in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma; however, the survival benefits are modest in patients with low programmed death ligand 1 (PD-L1) expression. Here we investigated the efficacy and safety of cadonilimab (PD-1/cytotoxic T lymphocyte antigen-4 (CTLA-4) bispecific antibody) plus chemotherapy as first-line treatment in G/GEJ adenocarcinoma. The prespecified interim analysis is reported here. This was a randomized, double-blind, placebo-controlled phase 3 study. Eligible patients were adults with untreated, unresectable, locally advanced or metastatic G/GEJ adenocarcinoma. Patients were randomized 1:1 to receive cadonilimab (10 mg kg

Indexed as

AdenocarcinomaAntibodies, BispecificAntineoplastic Combined Chemotherapy ProtocolsErb-b2 Receptor Tyrosine KinasesEsophageal NeoplasmsEsophagogastric JunctionStomach NeoplasmsAdultAgedAntibodies, Monoclonal, HumanizedB7-H1 AntigenDouble-Blind MethodFemaleHumansMaleMiddle AgedAntibodies, BispecificAntibodies, Monoclonal, HumanizedB7-H1 AntigenCD274 protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases

Identifiers

PMID39843940

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.